Benzoic Acid

Benzoic Acid

SCHEMBL9928995

CCc1nc(C)c[nH]1.O=C(O)c1ccccc1

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CACNA1CCACNA1DCACNA1FCACNA1SDPP4HTR1BHTR1D

The experimentally established mechanism targets of Benzoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.44
TSHR P16473 1/20 0.44
NAPRT Q6XQN6 1/20 0.44
ALDH1A1 P00352 2/20 0.41
CES2 O00748 2/20 0.39
CES1 P23141 2/20 0.39
SRD5A2 P31213 1/20 0.39
RXRA P19793 2/20 0.39
NR4A2 P43354 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4D Q08499 1/20 0.39
HSD17B10 Q99714 1/20 0.37
TP53 P04637 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
NOTUM Q6P988 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
HTT P42858 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
VCP P55072 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Citrazinic Acid SCHEMBL15022514 0.82 NOTUM (0.39) DAOTSHRALDH1A1HSD17B10NOTUM
SCHEMBL17961177 0.79 SMN1; SMN2 (0.47) TSHRALDH1A1HSD17B10TP53L3MBTL1
SCHEMBL11333696 0.77
SCHEMBL11854680 0.77
Boric Acid SCHEMBL5724736 0.76 ADORA1 (0.34)
SCHEMBL15022628 0.75 KDM4E (0.41) TSHRALDH1A1HSD17B10TP53SMN1; SMN2
SCHEMBL2023841 0.72 ADORA1 (0.34) TP53L3MBTL1
Benzoic Acid SCHEMBL28693411 0.71 TSHR (0.78) DAOTSHRNAPRTALDH1A1CES2
Benzoic Acid SCHEMBL9705228 0.71 TSHR (0.78) DAOTSHRNAPRTALDH1A1CES2
Benzoic Acid SCHEMBL2400344 0.71 TSHR (0.78) DAOTSHRNAPRTALDH1A1CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455573-B2 Curable composition comprising imidazolium monocarboxylate salt E I DU PONT DE NEMOURS AND COMPANY (US) 2013-06-04 US claimed
WO-2012088158-A2 CURABLE EPOXY COMPOSITION COMPRISING IMIDAZOLIUM SALTS AND METHOD FOR CURING SAME E. I. DU PONT DE NEMOURS AND COMPANY (US) 2012-06-28 WO claimed
WO-2012088163-A2 METHOD FOR PREPARING A CONFORMALLY SEALED PRINTED WIRING BOARD USING A COATED SUBSTRATE COMPRISING A CURABLE EPOXY COMPOSITION COMPRISING IMIDAZOLIUM SALTS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2012-06-28 WO claimed
WO-2012088160-A2 A COATED SUBSTRATE COMPRISING A CURABLE EPOXY COMPOSITION COMPRISING IMIDAZOLIUM SALTS AND METHOD FOR PREPARING SAME E. I. DU PONT DE NEMOURS AND COMPANY (US) 2012-06-28 WO claimed
WO-2012088148-A2 LATENT CURE CATALYST BASED UPON IMIDAZOLIUM SALTS USEFUL FOR EPOXY COMPOSITIONS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2012-06-28 WO claimed
US-20120157572-A1 CURABLE COMPOSITION COMPRISING IMIDAZOLIUM MONOCARBOXYLATE SALT E.I. DU PONT DE NEMOURS AND COMPANY (US) 2012-06-21 US claimed
US-20120152458-A1 METHOD FOR PREPARING MULTILAYER ARTICLE BY CURING A CURABLE COMPOSITION COMPRISING IMIDAZOLIUM MONOCARBOXYLATE SALT E. I. DU PONT DE NEMOURS AND COMPANY (US) 2012-06-21 US claimed
US-20120156474-A1 ARTICLE HAVING CURABLE COATING COMPRISING IMIDAZOLIUM MONOCARBOXYLATE SALT E. I. DU PONT DE NEMOURS AND COMPANY (US) 2012-06-21 US claimed
US-20120157688-A1 IMIDAZOLIUM MONOCARBOXYLATE SALT AND METHOD FOR PREPARATION THEREOF E. I. DU PONT DE NEMOURS AND COMPANY (US) 2012-06-21 US claimed
US-8455573-B2 Curable composition comprising imidazolium monocarboxylate salt E I DU PONT DE NEMOURS AND COMPANY (US) 2013-06-04 US disclosed
WO-2012088160-A2 A COATED SUBSTRATE COMPRISING A CURABLE EPOXY COMPOSITION COMPRISING IMIDAZOLIUM SALTS AND METHOD FOR PREPARING SAME E. I. DU PONT DE NEMOURS AND COMPANY (US) 2012-06-28 WO disclosed
WO-2012088163-A2 METHOD FOR PREPARING A CONFORMALLY SEALED PRINTED WIRING BOARD USING A COATED SUBSTRATE COMPRISING A CURABLE EPOXY COMPOSITION COMPRISING IMIDAZOLIUM SALTS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2012-06-28 WO disclosed
WO-2012088158-A2 CURABLE EPOXY COMPOSITION COMPRISING IMIDAZOLIUM SALTS AND METHOD FOR CURING SAME E. I. DU PONT DE NEMOURS AND COMPANY (US) 2012-06-28 WO disclosed
WO-2012088148-A2 LATENT CURE CATALYST BASED UPON IMIDAZOLIUM SALTS USEFUL FOR EPOXY COMPOSITIONS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2012-06-28 WO disclosed
US-20120157688-A1 IMIDAZOLIUM MONOCARBOXYLATE SALT AND METHOD FOR PREPARATION THEREOF E. I. DU PONT DE NEMOURS AND COMPANY (US) 2012-06-21 US disclosed
US-20120157572-A1 CURABLE COMPOSITION COMPRISING IMIDAZOLIUM MONOCARBOXYLATE SALT E.I. DU PONT DE NEMOURS AND COMPANY (US) 2012-06-21 US disclosed
US-20120152458-A1 METHOD FOR PREPARING MULTILAYER ARTICLE BY CURING A CURABLE COMPOSITION COMPRISING IMIDAZOLIUM MONOCARBOXYLATE SALT E. I. DU PONT DE NEMOURS AND COMPANY (US) 2012-06-21 US disclosed
US-20120156474-A1 ARTICLE HAVING CURABLE COATING COMPRISING IMIDAZOLIUM MONOCARBOXYLATE SALT E. I. DU PONT DE NEMOURS AND COMPANY (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157688-A1 IMIDAZOLIUM MONOCARBOXYLATE SALT AND METHOD FOR PREPARATION THEREOF EHMT2, EHMT1, PICALM DAO 2428/4885TSHR 4884/4885NAPRT 1551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.